BioSpace News Archive

Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, announced that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets.

ProMIS Neurosciences Inc. announced the publication of a paper titled, “Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies,” in the online journal, bioRxiv.

Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, presented updated Phase 1 data from its CORAL-CEPI study, a Coalition for Epidemic Preparedness Innovations -funded study that is evaluating Gritstone’s self-amplifying mRNA vaccine against COVID-19 in HIV-negative and people living with HIV participants.

Oncolytics Biotech ® Inc. today announced that it will host a conference call and webcast on Thursday, May 9, 2024.

Newron Pharmaceuticals S.p.A. announced positive top-line results from its potentially pivotal study 008A, evaluating the safety, tolerability and efficacy of evenamide in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic including clozapine, but demonstrating an inadequate response to that treatment.

Debiopharm and Repare Therapeutics Inc. announced that the first patient has been dosed in Module 4 of the ongoing Phase 1/1b MYTHIC clinical trial, investigating the combination of Debio 0123 and lunresertib.

Invivyd, Inc. announced that following a comprehensive strategic review, the company is improving its projected 2024 year-end cash position by approximately $20 million to $25 million.

Palatin Technologies, Inc., a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced it will host a virtual KOL event on Wednesday, May 8, 2024 at 10:00 AM ET.

Tenax Therapeutics, Inc. announced that the United States Patent and Trademark Office has granted the Company a patent covering the use of TNX-103, TNX-102, TNX-101, the active metabolites of levosimendan and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients.

TriLink BioTechnologies, a Maravai™ LifeSciences company and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries.